Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 7/20 | 0.63 |
| ▸ | CTSK | P43235 | 7/20 | 0.60 |
| ▸ | CTSB | P07858 | 3/20 | 0.58 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.57 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7134291 | 0.93 | CTSL (0.58) | CTSLCTSKCTSBCAPN1CTSS | |
| SCHEMBL1701577 | 0.91 | CTSL (0.55) | CTSLCTSKCTSBCTSS | |
| SCHEMBL8098620 | 0.91 | CTSL (0.55) | CTSLCTSKCTSBCTSS | |
| SCHEMBL8972275 | 0.90 | CTSK (0.60) | CTSLCTSKCTSBCAPN1CTSS | |
| SCHEMBL16847835 | 0.88 | CTSK (0.69) | CTSLCTSKCTSBCAPN1CTSS | |
| SCHEMBL8823948 | 0.88 | CTSK (0.65) | CTSLCTSKCTSBCAPN1CTSS | |
| SCHEMBL7796791 | 0.84 | CTSL (0.67) | CTSLCTSKCTSBCAPN1CTSS | |
| SCHEMBL7764593 | 0.84 | CTSL (0.65) | CTSLCTSKCTSBCAPN1CTSS | |
| SCHEMBL7330463 | 0.82 | CTSL (0.67) | CTSLCTSKCTSBCAPN1CTSS | |
| SCHEMBL7268416 | 0.82 | CAPN1 (0.58) | CTSLCTSKCTSBCAPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | CTSL 14/4885CTSK 29/4885CTSB 11/4885 |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CTSL 18/4885CTSK 32/4885CTSB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.